INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the ...
Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the ...
The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results